Dengue, also known as breakbone fever, is a painful and sometimes fatal viral disease characterized by headache, skin rash and debilitating muscle and joint pains. In some cases, it can lead to circulatory failure, shock, coma and death. The incidence of dengue has grown dramatically around the world in recent decades, and the latest figures estimate that there are 96 million symptomatic cases of dengue around the world each year. Dengue is now endemic in over 120 countries across the globe, and is the most prevalent mosquito-borne viral disease.
Combating dengue requires improved surveillance and country preparedness, as well as collaborations across countries and industries. Through its projects and partnerships Sabin is working to improve disease information and raise the profile of dengue. One of its projects is the Dengue Vaccine Initiative (DVI), for which Sabin works with as the advocacy arm. The other DVI consortium members are the World Health Organization, the International Vaccine Access Center at Johns Hopkins University and the International Vaccine Institute. DVI’S work builds on the capabilities of the consortium members and DVI partners to lay the groundwork for dengue vaccine introduction.